People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes ...

The FDA has approved a new indication for semaglutide to lower the risk for worsening kidney disease, kidney failure and ...

Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than ...

Topline data were announced from a phase 3b trial evaluating investigational semaglutide 7.2mg in adults with obesity.

compounded semaglutide comes in various concentrations. Reports received by the FDA found that healthcare providers have often miscalculated doses when converting from milligrams to units or ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...

At baseline, a physical examination and laboratory tests were conducted. An eleven-week semaglutide drug dose titration period was started, and during this period, all participants continued using ...

New study reveals semaglutide ... and high or low dosage of medication. The likelihood of achieving 10% or more weight loss at one year was 2% higher for every unit increase in baseline BMI.

It is particularly common after starting the medication and increasing your dose. But there’s a silver lining: Semaglutide nausea should go away as your body gets used to the medication.

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is rolling out new data on a higher-dose injection in obesity. In the phase 3b ...